Related Experiment Videos
[Myocardial protection in the patient with angina: bases for a personalized treatment]
1Divisione di Cardiologia, IRCCS, Policlinico San Matteo, Pavia.
Insights
Selecting the right drugs is key for secondary cardioprotection in angina pectoris patients. Different medications like calcium-channel blockers and beta-blockers offer specific benefits for various angina types and patient conditions.
Area of Science:
- Cardiology and Pharmacology
- Focuses on cardiovascular disease management and therapeutic interventions.
Context:
- Angina pectoris management requires tailored secondary cardioprotection strategies.
- Understanding the specific pathogenetic roles of vasoconstriction and ischemia is crucial.
Purpose:
- To outline optimal drug selection for secondary cardioprotection in angina pectoris.
- To differentiate the roles of various drug classes based on clinical presentation.
Summary:
- Calcium-channel blockers are indicated for vasospastic angina or conditions involving vasoconstriction.
- Beta-blockers are recommended for unstable angina to reduce mortality and myocardial infarction.
- Aspirin improves survival in unstable angina; ACE-inhibitors reduce mortality and unstable angina incidence in ischemic cardiomyopathy.
Impact:
- Provides evidence-based guidance for clinicians to optimize angina treatment.
- Highlights the importance of personalized pharmacotherapy for cardiovascular risk reduction.
- Suggests potential benefits of non-pharmacologic interventions, warranting further research.
Abstract:
Secondary cardioprotection of patients with angina pectoris can be accomplished by selecting appropriate drugs for the specific clinical setting. Calcium-antagonists are the first choice drugs in patients with vasospastic angina or in those clinical situations in which vasoconstriction plays a significant pathogenetic role. On the contrary beta-blockers reduce mortality and the probability of myocardial infarction in patients with unstable angina. The beneficial effects of aspirin on survival of patients with unstable angina is also well known, whereas ACE-inhibitors reduce mortality as well as the incidence of unstable angina in patients with ischemic cardiomyopathy. Also nonpharmacologic treatments (physical exercise, preconditioning) may have beneficial effects although their role is not well established yet.